-
1.发明授权Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism 失效通过确定TAFI-Ile347多态性来鉴定血栓形成障碍风险的方法公开(公告)号：US08420321B2
公开(公告)日：2013-04-16
申请号：US13109111
申请日：2011-05-17
申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
2.发明授权Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism 失效通过确定TAFI-Ile347多态性来鉴定血栓形成障碍风险的方法公开(公告)号：US07560290B2
公开(公告)日：2009-07-14
申请号：US11184010
申请日：2004-04-01
申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，选择患有血栓形成疾病风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法，以及 通过采用TAFI-Ile347多态性制备药物和诊断方法。
-
3.发明申请METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM 失效通过确定TAF1-lle347多态性鉴定致病性疾病风险的方法公开(公告)号：US20110223628A1
公开(公告)日：2011-09-15
申请号：US13109111
申请日：2011-05-17
申请人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
发明人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
IPC分类号： C12Q1/37
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
4.发明授权Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism 失效通过确定TAFI-ILE347多态性来鉴定血栓形成障碍风险的方法公开(公告)号：US07985562B2
公开(公告)日：2011-07-26
申请号：US12474794
申请日：2009-05-29
申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
IPC分类号： G01N33/00
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder, to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，选择患有血栓形成疾病风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法，以及 通过采用TAFI-Ile347多态性制备药物和诊断方法。
-
5.发明申请METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM 失效通过确定TAF1-ILE47多态性来识别致病性疾病的风险的方法公开(公告)号：US20090239237A1
公开(公告)日：2009-09-24
申请号：US12474794
申请日：2009-05-29
申请人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
发明人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
IPC分类号： C12Q1/68
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
6.发明申请Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-IIe347 polymorphism 失效通过确定TAFI-IIe347多态性来鉴定血栓形成障碍风险的方法公开(公告)号：US20060040296A1
公开(公告)日：2006-02-23
申请号：US11184010
申请日：2004-04-01
申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
发明人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.01 秒)
